This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MannKind: Great Trade; Good Investment?

CHARLOTTE, N.C. ( Stockpickr) -- On Aug. 14, MannKind ( MNKD) reported long-awaited positive phase III results from two clinical trials of its Afrezza insulin and inhaler product. Now the company finds itself faced with a fascinating mixture of positives, negatives and uncertainties, guaranteeing that MNKD will be an excellent trading stock -- with the whipsaw price-movements so dearly loved by traders -- for the foreseeable future.

>>5 Stocks Poised for Breakouts

But couldn't MNKD also represent an exceptional investment right now, as well?

Let's look at it from both angles, after neatly categorizing the positives, negatives and uncertainties.


1. Clinical trials for both type 1 and type 2 diabetes patients met the primary endpoints sought by the company and, presumably, the FDA.

2. Afrezza, by itself or in combination with an oral insulin product, was well-tolerated by nearly 100% of participating patients.

3. The trials showed that Afrezza, by itself or in combination with an oral insulin product, may well reduce or eliminate many diabetics' reliance on injected insulin.

4. As the FDA has, in the past, already approved Exubera -- widely perceived to be an inferior product compared to Afrezza -- FDA approval of Afrezza in early 2014 should be a near-certainty.

>>4 Biotech Stocks Under $10 Making Big Moves

5. Exubera was pulled by Pfizer ( PFE) in 2007, so if approved by the FDA, Afrezza will hold an absolute monopoly on the inhaled-insulin market, which many believe to be initially worth $3 billion yearly.


1. Approximately one-third of patients participating in the Afrezza clinical trials experienced, as a side effect, a mild cough and a slightly lessened exhaling power of the lungs.

2. A greater number of Afrezza patients experienced low blood sugar, compared with patients using injected insulin.

3. Doctors have for many decades been totally familiar with the use and prescribing of injected insulin. Afrezza will be totally new to them, with regards to dosage, performance, side effects and so on.

4. Exubera, Pfizer's inhaled-insulin product previously approved by the FDA, proved to be a commercial failure, losing $3 billion for that company and leading them to pull out of the market after only one year. Many fear that AFREZZA may suffer a similar lack of commercial success.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,138.71 -33.97 -0.20%
S&P 500 1,990.57 -3.72 -0.19%
NASDAQ 4,519.5970 -8.0920 -0.18%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs